Clinical Pharmacology Study of CS-3150 A single-dose study to assess the pharmacokinetics and safety of CS-3150 in Japanese subjects with varying degrees of hepatic function
Latest Information Update: 07 Dec 2021
Price :
$35 *
At a glance
- Drugs Esaxerenone (Primary)
- Indications Diabetic nephropathies; Essential hypertension; Hypertension
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 08 Nov 2019 Results assesing pharmacokinetics and safety of a single oral dose of esaxerenone were published in the Advances in Therapy
- 28 Aug 2017 Status changed from active, no longer recruiting to completed.
- 28 Jun 2017 Status changed from recruiting to active, no longer recruiting.